Corrigendum to "Potency, toxicity and protection evaluation of PastoCoAd candidate vaccines: Novel preclinical mix and match rAd5 S, rAd5 RBD-N and SOBERANA dimeric-RBD protein" [Vaccine 40(20) (2022) 2856-2868]
Vaccine. 2022 Nov 15;40(48):7009.
doi: 10.1016/j.vaccine.2022.10.019.
Epub 2022 Oct 28.
1 COVID-19 National Reference Laboratory, Pasteur Institute of Iran, Tehran, Iran; Department of Arboviruses and Viral Hemorrhagic Fevers (National Reference Laboratory), Pasteur Institute of Iran, Tehran, Iran.
2 Department of Virology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
3 National Reference Laboratory for Plague, Tularemia and Q Fever, Research Center for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Akanlu, Kabudar Ahang, Hamadan, Iran; Department of Epidemiology and Biostatistics, Research Center for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran.
4 Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran; Amirabad Virology Laboratory, Vaccine Unit, Tehran, Iran.
5 Research and Production Complex, Pasteur Institute of Iran, Tehran, Iran.
6 Department of Production, Research and Production Complex, Pasteur Institute of Iran, Tehran, Iran.
7 Department of Molecular Virology, Pasteur Institute of Iran, Tehran, Iran.
8 Finlay Vaccine Institute, Havana, Cuba.
9 Pasteur Institute of Iran, Tehran, Iran. Electronic address: biglari63@hotmail.com.
10 Department of Hepatitis and AIDS, Pasteur Institute of Iran, Tehran, Iran. Electronic address: k_baesi@pasteur.ac.ir.